Back to top

messenger-rna: Archive

Zacks Equity Research

MRNA Beats on Q2 Earnings & Sales, Stock Down on Lowered Sales View

MRNA tops Q2 estimates with a narrower loss and revenue beat, but the stock slips after trimming 2025 sales guidance.

PFEPositive Net Change MRKPositive Net Change MRNAPositive Net Change BNTXPositive Net Change